3 ms·
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31022-9/fulltext https://www.thelancet.com/journals/lancet/article/PIIS0140-6... is the gold
by akimball 6y ago
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31022-9/fulltext https://www.thelancet.com/journals/lancet/article/PIIS0140-6... is the gold standard placebo-controlled double-blind RCT. It shows no significant benefits, substantial adverse effects. Also published today, but no headlines
- vikramkr 6y agoThe adverse effects are concerning, however, the lancet trial was underpowered and had to be stopped early because there weren't enough patients [0]. That's why they say in their interpretation that even though they saw some numerical improvement in their results, larger trials are needed to evaluate statistical significance. The NIAID's trial is also a placebo-controlled randomized controlled trial and was adequately powered for reduction in recovery time, but didn't hit statistical significance at a p<.05 threshold for mortality rate. [0]https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31023-0/fulltext https://www.thelancet.com/journals/lancet/article/PIIS0140-6...
- xiphias2 6y agoIt had just 237 participants, so it makes sense that it didn't show significant difference.
- abracada_toss 6y agoHi, I read about lancet trial in news actually ... it is not "powered" ... not enough patients. they say the wuhan virus went away before trial finish.